| 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party M Heuser, SD Freeman, GJ Ossenkoppele, F Buccisano, CS Hourigan, ... Blood, The Journal of the American Society of Hematology 138 (26), 2753-2767, 2021 | 400 | 2021 |
| Identification of a small subpopulation of candidate leukemia-initiating cells in the side population of patients with acute myeloid leukemia B Moshaver, A Van Rhenen, A Kelder, M Van Der Pol, M Terwijn, ... Stem cells 26 (12), 3059-3067, 2008 | 137 | 2008 |
| The role of minor subpopulations within the leukemic blast compartment of AML patients at initial diagnosis in the development of relapse C Bachas, GJ Schuurhuis, YG Assaraf, ZJ Kwidama, A Kelder, F Wouters, ... Leukemia 26 (6), 1313-1320, 2012 | 114 | 2012 |
| High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine C Bachas, GJ Schuurhuis, IHIM Hollink, ZJ Kwidama, BF Goemans, ... Blood, The Journal of the American Society of Hematology 116 (15), 2752-2758, 2010 | 95 | 2010 |
| Targeting the cell cycle in head and neck cancer by Chk1 inhibition: a novel concept of bimodal cell death AM van Harten, M Buijze, R van der Mast, MA Rooimans, ... Oncogenesis 8 (7), 38, 2019 | 60 | 2019 |
| Technical aspects of flow cytometry-based measurable residual disease quantification in acute myeloid leukemia: experience of the European LeukemiaNet MRD Working Party JM Tettero, S Freeman, V Buecklein, A Venditti, L Maurillo, W Kern, ... Hemasphere 6 (1), e676, 2022 | 51 | 2022 |
| Computational analysis of flow cytometry data in hematological malignancies: future clinical practice? C Duetz, C Bachas, TM Westers, AA van de Loosdrecht Current Opinion in Oncology 32 (2), 162-169, 2020 | 39 | 2020 |
| 2021 update measurable residual disease in acute myeloid leukemia: European leukemia net working party consensus document M Heuser, SD Freeman, GJ Ossenkoppele, F Buccisano, CS Hourigan, ... Blood 138 (26), 2753-2767, 2021 | 38 | 2021 |
| Gene expression profiles associated with pediatric relapsed AML C Bachas, GJ Schuurhuis, CM Zwaan, MM van den Heuvel-Eibrink, ... PLoS One 10 (4), e0121730, 2015 | 35 | 2015 |
| Computational flow cytometry as a diagnostic tool in suspected‐myelodysplastic syndromes C Duetz, S Van Gassen, TM Westers, MF van Spronsen, C Bachas, ... Cytometry Part A 99 (8), 814-824, 2021 | 27 | 2021 |
| Clinical relevance of molecular aberrations in paediatric acute myeloid leukaemia at first relapse C Bachas, GJ Schuurhuis, D Reinhardt, U Creutzig, ZJ Kwidama, ... British journal of haematology 166 (6), 902-910, 2014 | 27 | 2014 |
| Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi‐centre setting D Hanekamp, AN Snel, A Kelder, WJ Scholten, N Khan, M Metzner, ... British journal of haematology 190 (6), 891-900, 2020 | 16 | 2020 |
| Harnessing gene expression profiles for the identification of ex vivo drug response genes in pediatric acute myeloid leukemia DGJ Cucchi, C Bachas, MM van den Heuvel-Eibrink, ST Arentsen-Peters, ... Cancers 12 (5), 1247, 2020 | 14 | 2020 |
| Re: Myeloblasts in normal bone marrows expressing leukaemia-associated immunophenotypes D Hanekamp, C Bachas, A van de Loosdrecht, G Ossenkoppele, J Cloos Pathology 52 (2), 289-291, 2020 | 13 | 2020 |
| Rscreenorm: normalization of CRISPR and siRNA screen data for more reproducible hit selection C Bachas, J Hodzic, JC van der Mijn, C Stoepker, HMW Verheul, ... BMC bioinformatics 19, 1-12, 2018 | 13 | 2018 |
| Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively … JM Tettero, LL Ngai, C Bachas, DA Breems, T Fischer, BT Gjertsen, ... Haematologica 108 (10), 2794, 2023 | 11 | 2023 |
| TP53 mutations and relevance of expression of TP53 pathway genes in paediatric acute myeloid leukaemia DGJ Cucchi, C Bachas, K Klein, S Huttenhuis, CM Zwaan, ... British journal of haematology 188 (5), 736-739, 2020 | 10 | 2020 |
| Prospective validation of the prognostic relevance of CD34+CD38– AML stem cell frequency in the HOVON-SAKK132 trial LL Ngai, D Hanekamp, F Janssen, J Carbaat-Ham, MAMA Hofland, ... Blood, The Journal of the American Society of Hematology 141 (21), 2657-2661, 2023 | 9 | 2023 |
| Characterization of myelodysplastic syndromes hematopoietic stem and progenitor cells using mass cytometry C Bachas, C Duetz, MF van Spronsen, J Verhoeff, JJ Garcia Vallejo, ... Cytometry Part B: Clinical Cytometry 104 (2), 128-140, 2023 | 8 | 2023 |
| Characteristics of leukemic stem cells in acute leukemia and potential targeted therapies for their specific eradication Q Hansen, C Bachas, L Smit, J Cloos Cancer Drug Resistance 5 (2), 344, 2022 | 6 | 2022 |
Jacqueline CloosResearch coordinator, Hematology, VU University Medical Center,在 vumc.nl 的电子邮件经过验证
